Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic Publisher Pubmed



Azimzadeh M1 ; Mohn N2 ; Ghane Ezabadi S3 ; Moghimi Esfandabadi Z4 ; Soleimani A5 ; Ranjbar E6 ; Jahromi M7 ; Seyedebrahimi R8 ; Skripuletz T2 ; Moharrami Kasmaie F9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Laboratory Sciences, Khomein University of Medical Sciences, Khomein, Iran
  2. 2. Department of Neurology, Hannover Medical School, Hannover, 30625, Germany
  3. 3. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Medical Laboratory Sciences, Faculty of Paramedicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
  6. 6. Department of Paramedical Sciences, Gonabad University of Medical Sciences, Gonabad, Iran
  7. 7. Department of Anatomical Science, School of Medicine, Isfahan University of Medical Science, Isfahan, Iran
  8. 8. Department of Anatomical Sciences, School of Medicine, Qom University of Medical Sciences, Qom, Iran
  9. 9. Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Biomolecules Published:2021


Abstract

A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Related Docs
View other Related Docs
1. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)
2. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
3. Covid-19 Among Patients With Multiple Sclerosis a Systematic Review, Neurology: Neuroimmunology and NeuroInflammation (2021)
4. Cytokines and Micrornas in Sars-Cov-2: What Do We Know?, Molecular Therapy Nucleic Acids (2022)
5. Potential Immune Indicators for Predicting the Prognosis of Covid-19 and Trauma: Similarities and Disparities, Frontiers in Immunology (2022)
6. Covid-19 Infection and Hospitalization Rate in Iranian Multiple Sclerosis Patients: What We Know by May 2021, Multiple Sclerosis and Related Disorders (2022)
7. Covid-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight With No Bystander Effect?, Multiple Sclerosis and Related Disorders (2021)
8. Assessment of Mental Health, Knowledge, and Attitude of Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Response to 2019 Novel Coronavirus, Neurological Sciences (2021)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (50)
Masoud Etemadifar (34)
Other Related Docs
9. Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of Covid-19 in Multiple Sclerosis: A Menactrims Registry Based Study, Multiple Sclerosis and Related Disorders (2024)
10. The Role of Cytokine Profile and Lymphocyte Subsets in the Severity of Coronavirus Disease 2019 (Covid-19): A Systematic Review and Meta-Analysis, Life Sciences (2020)
11. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
12. A Multi-Centre Longitudinal Study Analysing Multiple Sclerosis Disease-Modifying Therapy Prescribing Patterns During the Covid-19 Pandemic, Journal of Neurology (2024)
13. Can Coronavirus Disease 2019 (Covid-19) Trigger Exacerbation of Multiple Sclerosis? a Retrospective Study, Multiple Sclerosis and Related Disorders (2021)
14. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)
15. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018, CNS Drugs (2021)
16. Impact of the Covid-19 Pandemic on the Psychological Status and Cortisol Level of Multiple Sclerosis Patients, Neuropsychological Rehabilitation (2023)
17. Supplementation With Vitamin D in the Covid-19 Pandemic?, Nutrition Reviews (2021)
18. Self-Reported Safety of the Bbibp-Corv (Sinopharm) Covid-19 Vaccine Among Iranian People With Multiple Sclerosis, Human Vaccines and Immunotherapeutics (2022)
19. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)
20. Covid-19 Susceptibility and Outcomes Among Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
21. Fear and Anxiety in Patients With Multiple Sclerosis During Covid-19 Pandemic; Report of an Iranian Population, Multiple Sclerosis and Related Disorders (2021)
22. Comparing the Consequences of Covid-19 Vaccination Between Central Nervous System (Cns) Demyelinating Diseases and Other Neurological Disorders, Vaccine (2024)
23. Cns Demyelinating Disease Following Inactivated or Viral Vector Sars-Cov-2 Vaccines: A Case Series, Vaccine (2023)
24. Nervous System Involvement in Covid-19: A Review of the Current Knowledge, Molecular Neurobiology (2021)
25. Multiple Sclerosis Disease-Modifying Therapies and Covid-19 Vaccines: A Practical Review and Meta-Analysis, Journal of Neurology, Neurosurgery and Psychiatry (2022)
26. Sars-Cov-2 Vaccines: A Double-Edged Sword Throughout Rapid Evolution of Covid-19, Cell Biology International (2022)
27. Effect of Multiple Sclerosis Disease-Modifying Therapies on the Real-World Effectiveness of Two Doses of Bbibp-Corv (Sinopharm) Vaccine, Journal of the Neurological Sciences (2023)
28. Risk and Severity of Sars-Cov-2 Reinfection Among Patients With Multiple Sclerosis Vs. the General Population: A Population-Based Study, BMC Neurology (2022)
29. The Clinical Manifestation and Outcome of Covid-19 in Patients With a History of Ischemic Heart Disease; a Retrospective Case-Control Study, BMC Cardiovascular Disorders (2023)
30. Prevention of Covid-19: Preventive Strategies for General Population, Healthcare Setting, and Various Professions, Advances in Experimental Medicine and Biology (2021)
31. Sars-Cov-2 (Covid-19): New Discoveries and Current Challenges, Applied Sciences (Switzerland) (2020)
32. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
33. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
34. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
35. Multiple Sclerosis Is Associated With Worse Covid-19 Outcomes Compared to the General Population: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
36. Outcome of Covid-19 Infection in Multiple Sclerosis Patients Receiving Disease-Modifying Therapies, Journal of Research in Medical Sciences (2021)
37. Epidemiology, Virology, Clinical Features, Diagnosis, and Treatment of Sars-Cov-2 Infection, Journal of Experimental and Clinical Medicine (Turkey) (2021)
38. T-Cell Immunophenotyping in Covid-19 Pneumonia, Journal of Research in Medical Sciences (2021)
39. Nanobased Platforms for Diagnosis and Treatment of Covid-19: From Benchtop to Bedside, ACS Biomaterials Science and Engineering (2021)
40. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis, JAMA Neurology (2018)
41. Aspects of Epidemiology, Pathology, Virology, Immunology, Transmission, Prevention, Prognosis, Diagnosis, and Treatment of Covid.19 Pandemic: A Narrative Review, International Journal of Preventive Medicine (2021)
42. Covid-19 Vaccines and Patients With Multiple Sclerosis: Willingness, Unwillingness and Hesitancy: A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
43. Recent Findings of Coronavirus: The Pathogenesis and Treatment, Journal of Isfahan Medical School (2020)
44. Covid-19 Management in the Emergency Ward, Journal of Research in Medical Sciences (2021)
45. Sars-Cov-2 Serology Among People With Multiple Sclerosis on Disease-Modifying Therapies After Bbibp-Corv (Sinopharm) Inactivated Virus Vaccination: Same Story, Different Vaccine, Multiple Sclerosis and Related Disorders (2022)
46. Myasthenia Gravis and Coronavirus Disease 2019: A Report From Iran, Current Journal of Neurology (2021)
47. The Outcomes of Covid-19 Epidemic Crisis on the Elderly: A Review Study, Journal of Isfahan Medical School (2021)
48. Characterizing the Immune Responses of Those Who Survived or Succumbed to Covid-19: Can Immunological Signatures Predict Outcome?, Cytokine (2021)
49. Fear of Re-Infection, Relapse, and Anxiety During Covid-19 Pandemic in Patients With Multiple Sclerosis: A Multi-Center Study, Current Journal of Neurology (2023)
50. Immune System Changes During Covid-19 Recovery Play Key Role in Determining Disease Severity, International Journal of Immunopathology and Pharmacology (2020)